More on OCS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.30 |
|
|||
| Open | $11.60 | ||||
| 52 Wk High | $8.14 | ||||
| 52 Wk Low | $6.68 | ||||
| Day High | $11.77 | ||||
| Day Low | $10.88 | ||||
| P/E | 374.00 | ||||
| EPS | $0.03 | ||||
| Volume | 772,599 | ||||
- H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)
- Oculis Holding AG (OCS) PT Lowered to $23 at JPMorgan
- Oculis Holding AG (OCS) PT Lowered to $38 at Baird
- Oculis Holding AG (OCS) PT Lowered to $45 at Guggenheim
- Oculis Holding AG (OCS) PT Lowered to $40 at Stifel After Disappointing Ph3 Results
- Oculis Holding AG (OCS) PT Lowered to $38 at Needham
- Oculis Holding AG (OCS) PT Lowered to $26 at H.C. Wainwright
- Form 6-K Oculis Holding AG For: May 29
- Oculis fails to meet primary endpoint in diabetic macular edema trials
- Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
Entities mentioned with OCS
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Definitive Agreement | View Related Stories »
- Robert W Baird | View Related Stories »
- 13G | View Related Stories »
- Show More...
